You are now leaving Kedrion Corporate site. Medical information including licensed uses may be different outside of the EU countries.
NO
YES
BACK TO ALL NEWS/

19-01-2016

Kedrion Biopharma strengthens its position on the US market

Kedrion Biopharma will commercialize a 10% concentrated intravenous liquid immunoglobulin (IVIg) on the US market, indicated for the treatment of Primary Immunodeficiencies (PI), on an exclusive basis. The product will enable the company, based in Castelvecchio Pascoli (Lucca), Italy’s leader and the 5th most important manufacturer of plasma-derived products in the world, to strengthen its immunoglobulin portfolio in the US.

The result is a seven year agreement signed with the US company Biotest Pharmaceuticals Corporation, a subsidiary of Biotest AG, Dreieich, Germany.

Kedrion Biopharma started its activities in the United States of America eleven years ago, opening three plasma-collection centers (now twelve). Over the years, the company’s US operations have also been boosted by a number of major investments, primarily the acquisition of a manufacturing plant in Melville, State of New York, in 2011, and the later acquisition of a division specializing in the manufacturing and marketing of a hyperimmune globulin used in the clinical practice for over half a century in the treatment of the Hemolytic Disease of the Fetus and the Newborn (HDFN).

The present agreement will enable Kedrion Biopharma to further increase the turnover generated by its operations in the US, which are currently the Lucca-based company’s main market (accounting, in 2014, for 160 Million Euros of company’s overall turnover of 466 Million Euros). In addition to which, this deal will have implications on Kedrion Biopharma’s activities in Italy too, as it has already been decided that, in the future, a phase of the manufacturing process (filling) will be carried out at the company’s facility in Bolognana, Lucca.

“Under this agreement – commented Paolo Marcucci, Kedrion Biopharma President and CEO – we will have the chance not only to grow further on what is considered  the most important market in the world; we will also be able to stand out as a market leader in plasma-derived therapies for the treatment of rare diseases. An area in which Kedrion Biopharma has been working hard since its foundation and with growing commitment, in partnership with patients’ associations, with the ultimate goal of broadening as much as possible the access to care for all those who need it.”

For more information please contact: investor@kedrion.com